1 result

    A phase 3, multi-center, double-blind, randomized, placebo-controlled, parallel-group study designed to investigate the efficacy and safety of CSL 112 (Apolipoprotein A-I: human) on reducing the risk of major adverse CV events in subjects with acute coronary syndrome (ACS) diagnosed with either ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI), including those managed with percutaneous coronary intervention (PCI) or medically managed.

    Type: Treatment

    Trial is open for enrollment

    View All Details

    • Principal Investigator:
      Sharan Mahal, MD

    For inquiries, call (908) 864-4027
    • Robert Wood Johnson University Hospital